18 18

Cited 0 times in

Programmed Cell Death-Ligand 1 Expression Status in Urothelial Carcinoma According to Clinical and Pathological Factors: A Multi-Institutional Retrospective Study

Authors
 Hyung Suk Kim  ;  Won Sik Jang  ;  Won Sik Ham  ;  Seung Il Jung  ;  Dong Hyun Lee  ;  Ja Hyeon Ku  ;  Hong Koo Ha  ;  Ja Yoon Ku  ;  Se Young Choi  ;  In Ho Chang  ;  Taesoo Choi  ;  Wan Song  ;  Seong Soo Jeon  ;  Byong Chang Jeong  ;  Sung Han Kim  ;  Ho Kyung Seo 
Citation
 FRONTIERS IN ONCOLOGY, Vol.10 : 568809, 2020-10 
Journal Title
 FRONTIERS IN ONCOLOGY 
Issue Date
2020-10
Keywords
immune cell ; immune checkpoint ; immunohistochemistry ; programmed cell death-ligand 1 ; urothelial carcinoma
Abstract
Purpose: To investigate programmed cell death-ligand 1 (PD-L1) expression status and the clinical and pathological factors related to its expression in urothelial carcinoma (UC) patients. Materials and Methods: Data from 761 UC patients who underwent testing for PD-L1 expression using the VENTANA (SP-142 immunohistochemistry assay) for measuring PD-L1 expression according to the manufacturer's protocol between February 2016 and July 2019 were retrospectively reviewed. Patients were categorized into three groups based on the percentage of tumor area covered by PD-L1-expressing tumor-infiltrating immune cells (ICs) as follows: IC0 (<1%), IC1 (≥1% and <5%), and IC2/3 (≥5%). Positive PD-L1 expression was defined as IC2/3 (≥5%). The factors related to positive PD-L1 expression were assessed by using unadjusted and adjusted logistic regression analyses. Results: In the entire cohort, 213 (28%) patients showed positive PD-L1 expression. Final adjusted regression analyses for positive PD-L1 expression revealed that several factors, including intravesical BCG prior to PD-L1 testing (odds ratio [OR] 0.57, 95% confidence interval [CI] 0.37-0.96), advanced tumor stage (stage III/IV) (OR 2.04, 95% CI 1.41-2.93), and high tumor grade (OR 5.31, 95% CI 2.38-11.83) were significantly associated with positive PD-L1 expression. Conclusions: This study showed that the PD-L1 expression is associated with several clinical and pathological factors for the first time in a real-world setting. Further follow-up clinical trials should consider adjusting these factors, including intravesical BCG treatment, tumor stage and grade to clarify the utility of PD-L1 as a biomarker.
Files in This Item:
T202005472.pdf Download
DOI
10.3389/fonc.2020.568809
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers
Yonsei Authors
Ham, Won Sik(함원식) ORCID logo https://orcid.org/0000-0003-2246-8838
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/181351
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links